Drug Insight: new drugs in development for Parkinson's disease

被引：0
作者：
Carlo Colosimo
Giovanni Fabbrini
Alfredo Berardelli
机构：
[1] University Department of Neurosciences and run the Movement Disorders Clinic,Department of Neurosciences and Neuromed Institute
[2] all at the University of Rome “La Sapienza”,Department of Neurological Sciences
[3] University of Rome “La Sapienza”,undefined
来源：
Nature Clinical Practice Neurology | 2006年 / 2卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Levodopa is the mainstay of treatment for Parkinson’s disease, but it is unable to halt the progression of the disease, and it is also associated with undesirable side effects, including motor fluctuations and dyskinesia. This Review highlights new therapeutic strategies in Parkinson's disease, including neuroprotective therapies and non-dopaminergic drugs, as well as improvements to the existing dopaminergic drugs.
引用
收藏
页码：600 / 610
页数：10
相关论文
共 91 条
[1]  
Nutt JG(1996)The response to levodopa in Parkinson's disease: imposing pharmacological law and order Ann Neurol 39 561-573
[2]  
Holford NH(1999)Motor fluctuations in Parkinson's disease: pathophysiology and treatment Eur J Neurol 6 1-21
[3]  
Colosimo C(1996)The motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications or the pathogenesis of the on-off phenomenon J Neurol Neurosurg Psychiatry 61 634-637
[4]  
De Michele M(2000)The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease Ann Neurol 47 S105-S114
[5]  
Colosimo C(2001)Pathophysiology of levodopa-induced dyskinesia: potential for new therapies Nat Rev Neurosci 2 577-588
[6]  
Brotchie JM(1992)Levodopa-induced dyskinesia: facts and fancy. What does the MPTP monkey model tell us? Can J Neurol Sci 19 134-137
[7]  
Bezard E(1998) administration of ropinirole and bromocriptine induces less dyskinesia than LD in the MPTP-treated marmoset Mov Disord 13 234-241
[8]  
Bedard PJ(2000)A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group N Engl J Med 342 1484-1491
[9]  
Pearce RKB(1994)Clinical usefulness of apomorphine in movement disorders Clin Neuropharmacol 17 243-259
[10]  
Rascol O(1990)Cognitive function in Parkinson's disease: from description to theory Trends Neurosci 13 21-29
12345678910